Rani Therapeutics Holdings, Inc. Class A (RANI)

Rani Therapeutics' stock has experienced volatility over the past six months. As of March 27, 2026, the share price was $0.81, a 40.40% decline from March 28, 2025. The stock has shown upward movement, with a 137.5% gain over the past six months, but is down approximately 16% year-to-date. Key events include a surge in October 2024, an oversubscribed private placement in October 2025, repayment of all outstanding debt in December 2025, and the release of Q4 and Full Year 2025 financial results in March 2026, which led to a negative market reaction despite improved liquidity.

As a clinical-stage biotherapeutics company, Rani Therapeutics' products are in development, so traditional demand seasonality does not apply. Demand is driven by clinical trial outcomes, regulatory approvals, and strategic partnerships. Stock price data suggests some seasonality in stock performance, reflecting investor sentiment rather than inherent product demand.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on transforming drug administration from injections to oral pills. Their core innovation is the RaniPill® capsule, an oral delivery platform for various drug substances. The company's product pipeline includes candidates like RT-102 for osteoporosis, RT-105 for psoriatic arthritis, RT-110 for hypoparathyroidism, RT-111 for inflammatory conditions, RT-114 for obesity (developed with ProGen), and RT-116 for obesity.

Rani Therapeutics is headquartered in San Jose, California, with a primary focus on the United States market. They have a collaboration with Chugai Pharmaceutical for global development and commercialization of an oral product. For RT-114, Rani will lead development and commercialization in the United States, Canada, Europe, and Australia, while ProGen leads in other countries.

Rani Therapeutics has a reputation as an innovative player in biotechnology, focused on revolutionizing drug delivery. Positive events impacting their brand reputation include a collaboration with Chugai Pharmaceutical, preclinical data demonstrating successful oral delivery of semaglutide, presentation of preclinical data demonstrating bioequivalence of RT-114, initiation of a Phase 1 study of RT-114, and the appointment of Jesper Høiland and Alireza Javadi. Despite positive advancements, the stock has experienced volatility, and the Q4 2025 earnings report saw a negative market reaction.

Rani Therapeutics' ownership is a mix of institutional, insider, and retail investors. Institutional investors own approximately 30.19% to 47.48% of the stock, insiders hold around 26.51% to 33.62%, and retail investors own approximately 23.24% to 29.51%. Major institutional owners include RA Capital Management, L.P., and Samsara BioCapital, LLC. The largest individual shareholder is Mir A. Imran, owning 20.48% of the company.